Omnia Biologics and Intradigm sign nanomedicine manufacturing deal
Contract manufacturer Omnia Biologics, based in Rockville, Maryland, US, is to provide process development and cGMP manufacturing services to its neighbouring drug development company Intradigm Corporation. The deal will accelerate Intradigm's clinical development programmes.
Contract manufacturer Omnia Biologics, based in Rockville, Maryland, US, is to provide process development and cGMP manufacturing services to its neighbouring drug development company Intradigm Corporation. The deal will accelerate Intradigm's clinical development programmes.
Intradigm is developing siRNA-derived therapeutics using proprietary nanomedicine technology and has led the advancement of siRNA from the test tube to a potent therapeutic class of gene specific inhibitors.
Omnia specialises in the contract manufacture of clinical trials materials for innovative biopharmaceuticals and ceo, Dr Dale VanderPutten, said: "Intradigm's technology has begun to transcend traditional notions of small molecules versus biologics by incorporating aspects of each. The advantages of this technology over current therapeutic regimes are enormous".